ReWalk Personal Exoskeleton by Lifeward

About

Lifeward (formerly ReWalk Robotics) received FDA clearance for the ReWalk Personal Exoskeleton for home and community use in 2014 — the first such clearance in history. In 2024, the Centers for Medicare & Medicaid Services finalised reimbursement for personal exoskeletons under the brace benefit category, with a reimbursement rate of $91,032 and 20% beneficiary copay. Major Medicare Advantage insurers including Humana, United Healthcare, and Aetna have also issued prior authorisation coverage.

What It Does

The ReWalk 7 is worn over regular clothing and uses motorised hip and knee joints, an onboard computer, and a wrist-worn controller to enable upright standing and walking for people with thoracic SCI. The programme includes a structured training phase with a certified therapist before home use is approved, and users must have a trained companion present during all walking sessions.

Who It Helps

Adults with thoracic spinal cord injury (T7 and below, AIS A or B) who meet medical eligibility criteria and are interested in exoskeleton-assisted walking for community mobility, rehabilitation, or secondary health benefits — as well as clinicians and families researching the leading FDA-approved, Medicare-eligible personal exoskeleton option.